Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Altimmune (ALT) Shares Outstanding (2016 - 2025)

Altimmune (ALT) has disclosed Shares Outstanding for 16 consecutive years, with $95.6 million as the latest value for Q3 2025.

  • On a quarterly basis, Shares Outstanding rose 34.41% to $95.6 million in Q3 2025 year-over-year; TTM through Sep 2025 was $95.6 million, a 34.41% increase, with the full-year FY2024 number at $72.4 million, up 2.37% from a year prior.
  • Shares Outstanding was $95.6 million for Q3 2025 at Altimmune, up from $85.1 million in the prior quarter.
  • In the past five years, Shares Outstanding ranged from a high of $95.6 million in Q3 2025 to a low of $38.3 million in Q1 2021.
  • A 5-year average of $58.7 million and a median of $52.7 million in 2023 define the central range for Shares Outstanding.
  • Peak YoY movement for Shares Outstanding: skyrocketed 149.08% in 2021, then increased 2.37% in 2024.
  • Altimmune's Shares Outstanding stood at $41.0 million in 2021, then rose by 20.02% to $49.2 million in 2022, then surged by 43.65% to $70.7 million in 2023, then rose by 2.37% to $72.4 million in 2024, then skyrocketed by 32.13% to $95.6 million in 2025.
  • Per Business Quant, the three most recent readings for ALT's Shares Outstanding are $95.6 million (Q3 2025), $85.1 million (Q2 2025), and $77.8 million (Q1 2025).